Evidence map›Paper›PMID 42211912›Full record

ArticleGynecology and pelvic medicine2025

Prognostic analysis of single-agent olaparib or combination cediranib and olaparib for platinum sensitive recurrent ovarian cancer: overall survival outcomes from NRG-GY004.

Yusuke Taira, Wataru Kudaka, Tomoko Nakamoto, Yoshihisa Arakaki, Yuko Shimoji, Natsuki Tamashiro, Masayuki Sekine

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecology and pelvic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yusuke TairaDepartment of Obstetrics and Gynecology, Graduate School of Medical Science University of the Ryukyus, Okinawa, Japan.
Wataru KudakaDepartment of Obstetrics and Gynecology, Graduate School of Medical Science University of the Ryukyus, Okinawa, Japan.
Tomoko NakamotoDepartment of Obstetrics and Gynecology, Graduate School of Medical Science University of the Ryukyus, Okinawa, Japan.
Yoshihisa ArakakiDepartment of Obstetrics and Gynecology, Graduate School of Medical Science University of the Ryukyus, Okinawa, Japan.
Yuko ShimojiDepartment of Obstetrics and Gynecology, Graduate School of Medical Science University of the Ryukyus, Okinawa, Japan.
Natsuki TamashiroDepartment of Obstetrics and Gynecology, Graduate School of Medical Science University of the Ryukyus, Okinawa, Japan.
Masayuki SekineDepartment of Obstetrics and Gynecology, Graduate School of Medical Science University of the Ryukyus, Okinawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cediranibOlaparibplatinum sensitiverecurrent ovarian cancer

Identifiers

PMID42211912
PMCPMC13215014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.